Memorial Sloan Kettering Cancer Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
- Conditions
- Urothelial CarcinomaLocally AdvancedUnresectable
- Interventions
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03093922
- Locations
- 🇺🇸
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale, New York, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
- Conditions
- Anaplastic Thyroid Cancer
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT03085056
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Commack (Limited Protocol Activities), Commack, New York, United States
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
- Conditions
- RefractoryRelapsedChronic Lymphocytic Leukemia (CLL)
- Interventions
- Biological: EGFRt/19-28z/4-1BBL CAR T cells
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT03085173
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Dye for the Detection of Cancer of the Tongue and Mouth
- Conditions
- Oral Squamous Cell Carcinoma (OSCC)
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT03085147
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester (Consent Only), Harrison, New York, United States
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
- Conditions
- Myeloid Hematologic MalignancyLymphoid Hematologic Malignancy
- Interventions
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03082677
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Risk Stratification Among Individuals Who Have Many Moles on Their Skin
- Conditions
- High-Risk Nevus Phenotype
- Interventions
- Behavioral: surveyOther: Saliva samples
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 73
- Registration Number
- NCT03080948
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant
- Conditions
- Intestinal MicrobiomeFebrile Neutropenia
- Interventions
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 347
- Registration Number
- NCT03078010
- Locations
- 🇺🇸
Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
- Conditions
- Lung CancerRecurrent Lung AdenocarcinomaLung AdenocarcinomaLung Cancer MetastaticLung Cancer Stage IVRecurrent Lung Cancer
- Interventions
- First Posted Date
- 2017-03-10
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT03076164
- Locations
- 🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03069326
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
- Conditions
- SarcomaEpithelioid SarcomaCutaneous Angiosarcoma
- Interventions
- Drug: Talimogene Laherparepvec (T-VEC)
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT03069378
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center (Data Analysis Only), Houston, Texas, United States
🇺🇸Enable Medicine (Specimen Analysis Only), Menlo Park, California, United States